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impacts in children and is currently being evaluated for use in adults in  
the Czech Republic (CR). The objective of this study was to assess the  
cost-effectiveness of pneumococcal vaccination strategies in the elderly 
population. METHODS: A first-order Markov decision-analytic model was 
developed to compare cost-effectiveness of vaccination with PCV13, PPSV23  
and no vaccination in the Czech Republic. PPSV23 effectiveness was derived 
from literature and PCV13 was extrapolated from impact in children adjusting 
for immunosenescence in older persons. Pneumonia, bacteremia and meningitis 
hospitalization and cost data were acquired from health authorities and  
DRG system in CR; outpatient data were based on retrospective patient survey. 
The model used a lifetime time horizon and 3% discount rate. RESULTS:  
Used according to Czech guidelines, PCV13 vaccination is associated with 0.0002 
life-years gained for an additional EUR 1.002 on average (EUR 3,812,478 in total) 
compared to no vaccination and 0.0004 life-years gained for additional EUR 0.97 
on average (EUR 3,704,061 in total) compared to PPSV23. This leads to an ICER  
of EUR/LYG 4,950 and 2,265 under current reimbursement. If all moderate  
and high risk people were vaccinated, the ICER would increase to EUR/LYG 5,582 
and 6,691, respectively, under current reimbursement and to ICER of EUR/LYG 
8,676 and 7,057 under full reimbursement. CONCLUSIONS: Confronting  
the national GDP per capita with the WHO recommendation on health care 
spending per QALY gained, PCV13 national immunization program in the Czech 
Republic can be considered cost-effective even under a full reimbursement 
policy.  
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OBJECTIVES: Chlamydia (CT), gonorrhea (GC) and trichomoniasis (TV) screening 
can be conducted simultaneously on a single sample using nucleic acid 
amplification testing (NAAT). NAAT has made screening faster and more 
sensitive. Targeted CT/GC screening has long been supported by clinical 
guidelines (USPSTF, CDC, and ACOG) and research has shown screening to be 
cost-effective from a health-system perspective. Despite this, testing rates are 
low (estimated at 38% by the CDC). Here, we explore the clinical and economic 
impact of increasing adherence to screening guidelines for CT/GC and the 
introduction of TV screening from a US payer perspective. METHODS: A 
decision-tree cost-impact model was developed to compare current screening 
rates for CT/GC with a hypothetical increase in CT/GC screening uptake and the 
addition of TV screening in women 15-24yrs. with high-risk sexual behavior. 
Model components included testing, treatment, confirmation of eradication, and 
adverse events for women 15-24. Inputs were based on published literature. The 
model examines member cost (excluding partner transmission) and clinical 
impact of an increase in screening uptake over 1 year. RESULTS: For a 
hypothetical member population of 5.0M, with a baseline CT/GC/TV prevalence 
of 4.7/2.2/8.4%, increasing CT/GC screening uptake by 10% and adding 
simultaneous TV screening has an incremental cost per additional STI detected 
over a 5-year, 7-year, and lifetime time horizon of $376.18, $272.26, and $30.01, 
respectively. The incremental cost per adverse event avoided was $2,239.00, 
$1,541.86, $182.22, respectively. Lifetime adverse events avoided (discounted) 
include: 215 cases of PID, 93 PID-related sequelae, 14 adverse pregnancy 
outcomes and 0.8 HIV cases. CONCLUSIONS: Given its high prevalence, high rate 
of asymptomatic cases and the severity of the health consequences, TV should 
be considered as part of a comprehensive STI screening strategy. Increasing 
targeted screening for CT/GC/TV could be a cost-effective way of improving 
women’s health and a health plan’s quality of care.  
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OBJECTIVES: Preterm birth (PTB) is a costly public health problem that causes 
significant neonatal morbidity and mortality. To determine cost-effectiveness of 
vaginal progesterone (VP) gel in the prevention of preterm birth (PTB), we 
developed a decision analytic model using data from the PREGNANT trial. 
METHODS: PREGNANT was a multi-center, international RCT in which 459 
women with singleton gestations and short cervix (10-20mm by transvaginal 
ultrasound) were randomized to daily VP 8% gel (n=235) or placebo (n=224). 
Patient-level trial data along with cost data from the literature were used to 
develop the model (TreeAge Pro 2011). Births were categorized by gestational age 
at delivery: PTB at <28 weeks, PTB at 28-31 weeks, PTB at 32-36 weeks, or full 
term (≥37 weeks). Costs ($US 2011) included cervical length screening, VP gel 
(treatment group only), antenatal hospitalizations, cerclage, and delivery 
hospitalization (maternal + neonatal costs). The main outcome measure was 
incremental cost-effectiveness, calculated as the difference in total costs 
between the VP gel group and the placebo group, divided by the difference in the 
number of PTB averted between the VP gel group and the placebo group. A 
probabilistic sensitivity analysis (PSA) with 10,000 simulations was used to 
determine cost-effectiveness when both cost and outcome data were varied 
within defined limits. RESULTS: Model base case incremental savings for VP 
were $12,354 and an incremental benefit of VP was 0.042 PTB averted 
(ICER=$21,063/PTB averted). The PSA indicated that VP gel is expected to be less 
costly and more effective than placebo in 79.2% of simulated cases, however, less 
costly but ineffective in 16.8% of simulated cases. CONCLUSIONS: VP gel is cost-
effective in the prevention of PTB in women with short cervix as compared to 
placebo in most cases. Results inform ongoing clinical controversies regarding 
the value of VP as a preventive modality for PTB.  
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OBJECTIVES: LNG-IUS-12 is a low-dose hormonal intrauterine contraceptive 
system for up to 3 years of use. This analysis aimed to evaluate the cost-
effectiveness of LNG-IUS-12 in comparison to short-acting reversible 
contraceptive (SARC) methods in a cohort of young women in the United States 
(US) from a third-party payer’s perspective. METHODS: A state-transition model 
was developed to assess cost-effectiveness of LNG-IUS-12 versus SARC methods 
over 3 years in 1000 women aged 20-29 years, the age group accounting for over 
half of all abortions in the US. SARC methods comprise of oral contraceptives, 
ring, patch and injections – methods commonly used by this cohort. The model 
consisted of three mutually exclusive health states: initial method, unplanned 
pregnancy (UP) and subsequent method. Subsequent method is represented by a 
mixed market-weighted contraceptive ‘basket’. Failure and discontinuation rates 
were based on published literature. Unit costs were taken from standard US 
databases. Cost and effectiveness metrics for SARC were weighted using market 
share data. The key model output was cost per UP avoided. One-way sensitivity 
analyses (OWSA) and probabilistic sensitivity analyses (PSA) were performed. 
RESULTS: LNG-IUS-12 dominated SARC, resulting in fewer UP (65.26 vs. 278.97) 
and lower total costs ($1,274,295USD vs. $1,822,836USD, a 43% saving) over 3 
years. The costs associated with subsequent method used by women who 
initiated LNG-IUS-12 were lower ($107,587USD vs. $230,024USD) due to lower 
failure and discontinuation rates of LNG-IUS-12. OWSA results were insensitive 
to variation in key input parameters. PSA results indicate a high probability of 
dominance as all iterations were less costly and more effective. CONCLUSIONS: 
From a third-party payer perspective, LNG-IUS-12 is a more cost-effective 
contraceptive option than SARC. Therefore, women switching from current SARC 
use to LNG-IUS-12 are likely to generate cost savings to third-party health care 
payers, driven principally by decreased UP-related expenditures and long-term 
savings in contraceptive costs.  
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OBJECTIVES: About 30% of all pregnancies end in first trimester and half of them 
present as an incomplete miscarriage. It is a significant health issue raising 
economic burden on the publicly funded health care system in the Bahamas. 
Surgical evacuation is the most commonly used treatment which involves 
operating theater and inpatient costs in cases of complications like cervical 
trauma, uterine perforation, hemorrhage and infection. The objective of this 
study was to conduct a cost effectiveness analysis (CEA) of medical management 
(Misoprostol) versus surgical procedure in the management of incomplete 
miscarriages in the Bahamas, from a societal perspective. METHODS: Cost and 
probabilities of outcomes were derived from the hospital data and published 
literature. Cost of medical and surgical management included direct & indirect 
costs viz. physician cost, procedure cost, cost of ultrasounds, drug cost, cost of 
hospital stay, complications & adverse events; loss of wages and cost of travel. 
Primary outcomes were treatment success and failure. A one way sensitivity 
analyses were conducted by varying the cost and success by 25% & 15%, 
respectively. RESULTS: The CEA showed that, medical management (US$719 per 
patient) was the least costly alternative to surgical procedure (US$2,135 per 
patient). The incremental cost effectiveness ratio (ICER) of medical management 
was - $1,416 and proved to be the dominant option being less expensive and 
having comparable treatment success. Results were sensitive to variations in 
costs by 25% and success rate by 15% indicating domination of medical 
management suggesting being less expensive both to the patient as well as to 
the payer. CONCLUSIONS: From a societal perspective, medical management 
appears to be the least costly approach for the treatment of incomplete 
miscarriages in the Bahamas; and should be considered as the first line 
management. Further investigations are needed to obtain costs savings on long 
term horizon.  
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OBJECTIVES: To evaluate the cost-effectiveness of levonorgestrel-releasing 
intrauterine system (LNG-IUS) as a long-term contraceptive method compared 
with similar methods, from the state perspective METHODS: A Markov chain 
model is developed to evaluate pregnancies avoided as outcome of interest. The 
model was built in monthly cycles at a five-year time horizon for a hypothetical 
cohort of 1,000 women of childbearing age and includes probabilities of 
